This Article  • Abstract  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (575)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in JAMA  Social Bookmarking   What's this?

Implications for Cardiovascular Event Reduction

Robert S. Rosenson, MD; Christine C. Tangney, PhD

JAMA. 1998;279:1643-1650.

ABSTRACT
Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statin therapy have demonstrated that baseline or treated low-density lipoprotein (LDL) cholesterol levels are only weakly associated with net coronary angiographic change or cardiovascular events. The beneficial effects of statins on clinical events may involve nonlipid mechanisms that modify endothelial function, inflammatory responses, plaque stability, and thrombus formation. Experimental animal models suggest that statins may foster stability through a reduction in macrophages and cholesterol ester content and an increase in volume of collagen and smooth muscle cells. The thrombotic sequelae caused by plaque disruption is mitigated by statins through inhibition of platelet aggregation and maintenance of a favorable balance between prothrombotic and fibrinolytic mechanisms. These nonlipid properties of statins may help to explain the early and significant cardiovascular event reduction reported in several clinical trials of statin therapy.

INTRODUCTION

Jump to Section  • Top  • Introduction  • Ldl and cardiovascular events  • The vulnerable plaque and...  • Ldl and atherothrombogenesis  • Thrombotic factors  • Conclusion  • Author information  • References

CLINICAL TRIALS of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statin therapy demonstrate an improvement in cardiovascular end points and coronary stenosis that is incompletely explained by the baseline or treated low-density lipoprotein (LDL) cholesterol level.^1-5 The beneficial effects of statins on clinical events may involve nonlipid mechanisms that modify endothelial function, inflammatory responses, plaque stability, and thrombus formation (Table 1, Figure 1). This article discusses several nonlipid mechanisms that may contribute to the cardiovascular event reduction observed in clinical trials of statin therapy.

View this table: [in this window] [in a new window] Table 1.—Potential Differential Mechanisms Beyond Lipid Lowering

View larger version (134K): [in this window] [in a new window] Coronary plaque disruption and major pathophysiological pathways as influenced by various statin therapies. This schematic diagram depicts an acute plaque disruption and resultant thrombus formation. Recirculation zones increase blood viscosity, which foster rapid plaque formation. NO indicates nitric oxide; PAI-1, plasminogen activator inhibitor 1; PGI2, prostacyclin; MCP-1, monocyte chemotactic protein 1; M-CSF, monocyte colony-stimulating factor; LDL, low-density lipoprotein; Ox-LDL, oxidized low-density lipoprotein; MM-LDL, minimally modified low-density lipoprotein; A, atorvastatin; C, cerivastatin; F, fluvastatin; L, lovastatin; P, pravastatin; and S, simvastatin.

LDL AND CARDIOVASCULAR EVENTS

Jump to Section  • Top  • Introduction  • Ldl and cardiovascular events  • The vulnerable plaque and...  • Ldl and atherothrombogenesis  • Thrombotic factors  • Conclusion  • Author information  • References

The LDL cholesterol levels serve as the focus of cholesterol treatment guidelines that were established to prevent coronary heart disease (CHD) in patients with hypercholesterolemia who are initially free of CHD and for those with established CHD.^6-9 Treatment guidelines target LDL cholesterol levels on the basis of epidemiological associations rather than clinical trial outcomes and, thus, promulgate the concept that the magnitude of LDL cholesterol reduction equates directly with a proportionate reduction in atherosclerotic burden and clinical cardiovascular events. The LDL cholesterol level is an important target of cardiovascular prevention; however, elevated LDL cholesterol levels identify less than one half of individuals who will die from CHD.^10-11 The LDL cholesterol concentrations had a sensitivity of 47% in predicting 10-year CHD death rates in the Lipid Research Clinics Prevalence Study.¹² Similar data are available from the Finnish cohort (n=444) of the Seven Countries Study for which only a modest correlation between serum cholesterol and 30-year CHD mortality was observed (r=0.42).¹¹ The revised National Cholesterol Education Program (NCEP II) guidelines⁷ that stratify risk by LDL cholesterol levels and conventional risk factors are no better in predicting risk.¹² The importance of LDL cholesterol levels on the prediction of CHD can be improved by concomitant measurements of high-density lipoprotein cholesterol levels,¹³ fibrinogen,^14-15 plasma viscosity,¹⁶ and C-reactive protein.¹⁵

Clinical trials with statin therapy are accompanied by comparable changes in LDL cholesterol levels, but varying reductions in cardiovascular events^3-5,17-30 (Table 2). The relationship between baseline and treated LDL cholesterol levels and cardiovascular end points has been evaluated in several clinical trials.^3-5 The Regression Growth Evaluation Statin Study (REGRESS) demonstrated that the effect of pravastatin on change in mean coronary artery segment diameter, minimum obstruction diameter, and clinical events was not influenced by baseline LDL cholesterol level.³ Similarly, the Scandinavian Simvastatin Survival Study reported that major coronary events were reduced by a similar amount regardless of the baseline LDL cholesterol level.⁴ The West of Scotland Coronary Prevention Study (WOSCOPS) evaluated the relationship between on-treatment LDL cholesterol levels or total cholesterol change and CHD risk⁵ using the Framingham CHD-risk model.³¹ The CHD event rate in pravastatin-treated patients was not related to the magnitude of LDL cholesterol level lowering when the LDL cholesterol level reduction ranged from 19% to 54%.⁵ The Framingham model accurately predicted the CHD event risk rate in the placebo group but underestimated the CHD risk reduction in the pravastatin therapy group by 35%. These analyses suggest that nonlipid mechanisms^32-33 may contribute to the cardiovascular event reduction in WOSCOPS²¹ and explain the early clinical benefit in this trial and several others.^{3, 17-18,20-21,34}

View this table: [in this window] [in a new window] Table 2.—Effect of Statins on Cardiovascular (CV) Event Reduction and LDL-Cholesterol Levels*

THE VULNERABLE PLAQUE AND ACUTE CORONARY SYNDROMES

Jump to Section  • Top  • Introduction  • Ldl and cardiovascular events  • The vulnerable plaque and...  • Ldl and atherothrombogenesis  • Thrombotic factors  • Conclusion  • Author information  • References

Coronary plaque rupture and erosions are recognized precipitants of thrombosis in acute myocardial infarction, unstable angina pectoris, and sudden death.^35-40 The vast majority of acute myocardial infarctions arise from atherosclerotic lesions that are minimal to moderate in severity as quantified by arteriography.^{38, 41} The rapid progression of subclinical coronary stenosis has led to an appreciation of the vulnerable plaque.^35-36

The characteristics of the typical vulnerable plaque include increased numbers of inflammatory cells, such as macrophages and T lymphocytes at the shoulder region of the plaque, a large lipid pool, few smooth muscle cells and collagen fibers, and a thin fibrous cap^37-39,42-44 (Figure 1). The content of macrophages and T lymphocytes within the plaque is an important determinant of plaque disruption. The macrophages release proteolytic enzymes that weaken a thin overlying fibrous cap and accelerate collagen degradation. T lymphocytes release interferon gamma (IFN-) at sites of human plaque disruption.⁴³ Interferon gamma inhibits smooth muscle cells from expressing interstitial collagen genes and provides a molecular basis for impaired collagen synthesis and inhibition of smooth muscle cell proliferation.^45-47 In addition to impaired synthesis of structural proteins, catabolism of the extracellular matrix by metalloproteinases (interstitial collagenase, gelatinases, stromelysins) can weaken the fibrous cap.³⁷ These matrix-degrading proteinases are expressed by macrophage-derived foam cells and smooth muscle cells that are exposed to inflammatory cytokines (interleukin 1 or tumor necrosis factor). Plaque erosion is characterized by endothelial cell loss, sparsely distributed inflammatory cells, clusters of smooth muscle cells, and proteoglycans at the luminal surface.⁴⁰

Experimental animal models demonstrate that statin therapy can stabilize atherosclerotic plaques.^48-49 These compositional changes include a reduction in extracellular lipid deposits and the area of macrophages in the intima and media, increase in collagen area and the ratio of collagen area to the area of extracellular lipid deposits, increase in smooth muscle cells, and less calcification and neovascularization in the intima. Lipid-lowering therapies may reduce cardiovascular risk not only through altering the arterial wall (endothelial dysfunction, atherogenesis, plaque stability), but also through their thrombogenic effects and effects on blood flow properties(Table 3).

View this table: [in this window] [in a new window] Table 3.—Comparison of Statins on Potential Mechanisms Influencing Plaque Stabilization and Thrombosis*

LDL AND ATHEROTHROMBOGENESIS

Jump to Section  • Top  • Introduction  • Ldl and cardiovascular events  • The vulnerable plaque and...  • Ldl and atherothrombogenesis  • Thrombotic factors  • Conclusion  • Author information  • References

Elevated LDL cholesterol levels are a major predisposing factor to atherosclerosis. Oxidized LDL impairs endothelial-dependent vasodilation, induces apoptosis of human endothelial cells via activation of a CPP32-like protease, a member of the interleukin 1–converting enzyme-like protease family,⁵⁰ and generates an inflammatory response. Oxidized LDL modifies the functional response of vascular smooth muscle cells to angiotensin II stimulation.⁵¹

Oxidized LDL inhibits nitric oxide synthase activity of platelets,^52-53 which promotes thrombus formation through an enhancement of fibrinogen binding to platelets.⁵⁴ Oxidized LDL binds to platelet activation factor, which is an intracellular proinflammatory regulator.⁵⁵ Modified LDL promotes tissue factor expression by monocytes, but LDL inhibits activation of the extrinsic coagulation pathway through binding to the tissue factor pathway inhibitor (TEPI).^56-57 The LDL levels correlate with vitamin K–dependent coagulation factors (and inhibitors) and fibrinogen levels⁵⁸; however, the significance of these relationships is unresolved.⁵⁹ In subjects with hypobetalipoproteinemia (LDL cholesterol level, <1.81 mmol/L [69.99 mg/dL]), levels of fibrinogen and fibrinolytic markers (plasminogen activator inhibitor 1 [PAI-1] antigen), tissue plasminogen activator inhibitor 1 antigen) are low and this association further supports the relationship between LDL and these hemostatic factors.⁶⁰ In addition, LDL contributes to atherothrombogenesis through an increase in plasma and blood viscosity as shown in in vitro experiments and supported by epidemiological studies.⁵⁹

Endothelial Function

Endothelial-mediated vasodilatation is impaired in hypercholesterolemia and atherosclerosis.^61-62 In coronary arteries of patients with atherosclerosis, cholesterol lowering with pravastatin and lovastatin improves endothelial function as evidenced by limiting acetylcholine-induced vasoconstriction (Table 3). ^63-65 While this improvement in endothelial function was not seen with simvastatin,⁶⁶ the LDL cholesterol–lowering therapy with simvastatin improves peripheral nitric oxide–mediated vascular relaxation.^67-70 The improved coronary blood flow and vasodilatory response with statin therapy alleviates transient ischemia in patients with stable angina pectoris^71-72 and improves myocardial perfusion.^73-74 In patients with mild hypertension, cardiovascular reactivity to angiotensin II and norepinephrine is diminished after 3 weeks of therapy with pravastatin.⁷⁵ Statin therapy can ameliorate endothelial dysfunction and contribute to the observed clinical benefits of those agents, and this improvement may be ascribed to LDL cholesterol lowering and antioxidant properties of statins.

Inflammation

An early step in atherogenesis involves monocyte adhesion to the endothelium and penetration into the subendothelial space. Oxidized LDL binds to the scavenger cell receptor on monocyte-derived macrophages and contributes to foam cell formation. Inflammatory cytokines secreted by macrophages and T lymphocytes can modify endothelial function, smooth muscle cell proliferation, collagen degradation, and thrombosis.^46-47,76-78 Cholesterol level lowering in experimental models is accompanied by a reduction of inflammatory cells within atherosclerotic plaque.^48-49,79-81 Subjects with hypercholesterolemia have increased adhesiveness of isolated monocytes to fixed endothelial cells in vitro, and this response is diminished with lovastatin and simvastatin.⁸¹ Hypercholesterolemic rats treated with fluvastatin have significantly attenuated leukocyte-adherence responses to platelet activation factor and leukotriene B₄.⁸¹

In patients with cardiac transplants, pravastatin may suppress the inflammatory response and inhibit natural killer cell activity in cyclosporin-treated patients.⁸² Although transplant vasculopathy is a distinct pathological entity from atherosclerotic vascular disease, the same inflammatory mediators may determine plaque vulnerability.

Effect of Lipid Composition on Plaque Stability

The relative content of cholesterol esters in plaque is an important factor influencing plaque stability. The pools of lipid-laden macrophage foam cells are nondistensible and do not absorb transmitted energy. Circumferential shear stress is concentrated on the fibrous cap that separates blood from the thrombogenic lipid core,^83-84 and plaque disruption exposes the underlying plaque components to blood components that initiate thrombogenesis.^85-86

Statins inhibit cholesterol ester accumulation in monocyte-derived macrophages either by reducing the availability of free cholesterol toward the enzyme acyl-coenzyme A cholesterol acyltransferase by trapping it in phospholipid-containing pools, or by inhibiting LDL endocytosis related to reduced synthesis of mevalonate or mevalonate by-products required for cholesterol esterification.⁸⁷ Kempen et al⁸⁸ reported a dose-dependent inhibition of cholesterol accumulation in macrophages that was greater with lovastatin and simvastatin than with pravastatin (Table 3). Lowering blood LDL cholesterol levels may facilitate plaque stability either through a reduction in size^89-90 or by an alteration of the physiochemical properties of lipid cores.^91-92 Hydrolysis of liquid cholesterol esters to solid cholesterol crystals can yield firmer plaques.

Another factor obscuring the relationship between LDL cholesterol levels and clinical events is the distribution of LDL subspecies within the plaque and the susceptibility of select LDL particles to oxidative modification. Small, dense LDL particles are more atherogenic than larger, buoyant particles, in part, because of enhanced oxidative susceptibility⁹³ and reduced total antioxidant defense.⁹⁴ The small LDL particle diameter is an independent predictor of myocardial infarction,^95-96 and a predominance of dense LDL particles (density, >1.0378 g/mL) predicted coronary arteriographic benefit in the Stanford Coronary Risk Intervention Project.⁹⁷

In the Kuopio Atherosclerosis Prevention Study (KAPS),²⁶ 3 years of pravastatin therapy prolonged the lag time of LDL lipoproteins (a measure of oxidation resistance), increased plasma and LDL vitamin E levels, and improved overall LDL antioxidant capacity (Table 3). ⁹⁸ Lovastatin and simvastatin have been shown to inhibit LDL oxidation and uptake by macrophages in studies of shorter duration.^99-105 Simvastatin treatment for 6 months maintains total antioxidant capacity of LDL particles; however, measurements of plasma antioxidants (ubiquinone, dolichol, -tocopherol, -carotene, and lycopene) were either reduced^103-104 or unchanged.¹⁰⁵ Tissue concentrations of ubiquinone may be reduced with certain statins as reported in animal studies.^106-107 In contrast, plasma ubiquinone levels fall with simvastatin therapy, whereas the concentration of ubiquinone in skeletal muscle biopsy specimens remains unchanged.¹⁰⁵ Overall, these data suggest that statin therapy does not alter tissue antioxidant balance but increases total antioxidant capacity of plasma.

Smooth Muscle Cell Proliferation and Collagen Synthesis

Smooth muscle cells foster plaque stabilization^{39, 108} through synthesis of macromolecules that strengthen the fibrous cap³⁷ and absorption of energy transmitted to the vessel wall, which reduces circumferential shear stress along the endothelial surface.^83-84 Mechanical stress serves as a stimulus for smooth muscle cell synthesis.¹⁰⁹ The smooth muscle cell also is involved in the normal healing process.^{39, 108} After a plaque ulcerates, the normal reparative process requires proliferation of vascular smooth muscle cells. Vascular smooth muscle cells regulate synthesis of interstitial collagens that are stimulated by transforming growth factor and platelet-derived growth factor and inhibited by IFN-.⁴⁷

The influence of statins on smooth muscle cell proliferation has been evaluated in cell cultures of human femoral and rat myocytes and carotid arteries of rabbits.^110-114 Balloon-mediated injury of rabbit carotid arteries caused intimal proliferation that was not inhibited in placebo- and pravastatin-treated rabbits, whereas this process was inhibited by treatment with all other statins.^{110, 112} In cell culture experiments, most statins (atorvastatin, cerivastatin, fluvastatin, simvastatin) except pravastatin inhibit smooth muscle cell proliferation and migration induced by the platelet-derived growth factor and fibrinogen.^111-112 The permissive action of pravastatin on smooth muscle cell proliferation may be an advantage for the reparative process that follows plaque ulceration.¹⁰⁸ The concentration of statin needed to inhibit smooth muscle cell proliferation in vivo is comparable to plasma levels observed in humans administered conventional doses of these agents.¹¹⁴

THROMBOTIC FACTORS

Jump to Section  • Top  • Introduction  • Ldl and cardiovascular events  • The vulnerable plaque and...  • Ldl and atherothrombogenesis  • Thrombotic factors  • Conclusion  • Author information  • References

Whether plaque disruption leads to an acute ischemic event depends, in part, on the propensity for thrombus to form on the damaged vessel wall. The thrombogenic response may be influenced by the thrombogenicity of the vessel wall components,⁸⁶ interaction of blood components with the lipid pool or smooth muscle cell and proteoglycan complexes, local blood flow properties, and circulating hemostatic factors. The prothrombotic factors that have been evaluated with the statins include tissue factor expression, platelet aggregation, fibrinogen, plasma viscosity, and fibrinolytic factors (Table 3).

Tissue Factor

Tissue factor and corresponding messenger RNA have been localized in macrophages of human atherosclerotic plaque.⁸⁵ Tissue factor serves as a cofactor for plasma factor VII and cellular receptor for factor VIIa and, thus, plays a central role as the initiator of the extrinsic coagulation pathway.¹¹⁵ Lipophilic statins (fluvastatin, simvastatin) suppress tissue factor expression by cultured human macrophages through inhibition of a geranylgeranylated protein involved in tissue factor biosynthesis.¹¹⁶ This effect on tissue factor was not observed with pravastatin.

The extrinsic coagulation activation pathway is counterbalanced by a serine protease inhibitor known as TEPI. TEPI binds to factor Xa, and this complex inhibits tissue factor–mediated coagulation through binding to the tissue factor—factor VIIa complex.^56-57 Circulating TEPI is transported by dense subspecies of LDL, lipoprotein(a) (Lp[a]), and high-density lipoprotein.¹¹⁷ TEPI activity is increased in subjects with heterozygous familial hypercholesterolemia,^118-119 and types IIa (by 70%, P<.001) and IIb (by 36%, P<.001) hyperlipoproteinemias.¹²⁰ Cholesterol level lowering with simvastatin reduces LDL and TEPI without a significant change in factor VIIc.¹¹⁸

Platelet Aggregation

Platelets from patients with elevated LDL levels are more sensitive to aggregating agents than are platelets of normocholesterolemic subjects.¹²¹ The LDL causes intracellular acidification through inhibition of Na⁺/H⁺ antiport in human platelets, which mobilizes intracellular calcium in the resting state and after stimulation with agonists.¹²² The adenosine diphosphate–induced fibrinogen binding to platelets is increased in a dose-dependent manner by LDL (0.5-2.0 g of protein per liter).¹²³ Simvastatin reduces platelet aggregation and thromboxane production after 4 to 24 weeks of therapy, whereas lipid lowering was observed by 2 weeks of treatment.^124-125 Lovastatin therapy has been accompanied by both an increase and a decrease in platelet count and adenosine diphosphate–induced platelet aggregation.^126-127 Pravastatin normalizes platelet-dependent thrombin generation in hypercholesterolemic subjects, but this effect is unaccompanied by a change in prostaglandin production.¹²⁸ Pravastatin also has been shown to reduce cytosolic calcium and platelet aggregation.¹²⁹

Statins may reduce platelet aggregation by changing the cholesterol content of platelet membranes, which alters membrane fluidity.¹²⁹ In an experimental model that simulates primary hemostasis, hypercholesterolemic patients treated with aspirin (325 mg/d) deposit more platelet aggregates on damaged porcine aorta than normocholesterolemic subjects, and this response was reduced by pravastatin therapy.¹³⁰ In hypercholesterolemic subjects treated with aspirin (325 mg/d) and randomized to either pravastatin or simvastatin at equivalent LDL cholesterol-lowering doses, pravastatin inhibited platelet-thrombus formation on an injured artery. This was not observed in simvastatin-treated patients.¹³¹ These latter studies suggest a differential effect of statins on tissue-dependent platelet aggregation.

Fibrinogen and Viscosity

Fibrinogen levels and plasma viscosity may be used to stratify cardiovascular risk in hypercholesterolemic patients with and without established CHD.^14-16 Elevated plasma viscosity may contribute to atherothrombosis through impaired microcirculatory flow, shear stress damage at the blood-endothelial interface, facilitation of plasma protein interaction with the endothelium in poststenotic recirculation zones, and increased propensity for thrombosis.¹³²

Several studies examining the influence of statins on fibrinogen levels in hypercholesterolemic patients have shown mixed results.¹³³ Lovastatin has been accompanied by 19% to 24% increases in fibrinogen levels in two 6-month studies of 26 and 49 patients, respectively,^{126, 134} and by 5% in a 12-month study of 260 patients.¹³⁵ Two other small, short-term studies of 15 and 35 patients reported no change in fibrinogen concentration.^136-137 In contrast, Mayer et al¹²⁷ found a significant 10% reduction in fibrinogen levels in 20 hypercholesterolemic patients treated with lovastatin after 16 weeks of therapy, with further reductions throughout the 12-month interval of the study. This study was limited by fibrinogen measurements made at monthly intervals without adjustment for multiple observations and selection of a second fibrinogen value at baseline that was 4% higher than the initial value.¹³³

Lovastatin has been accompanied by an increase in whole blood viscosity,¹²⁶ while plasma viscosity is either reduced¹³⁶ or does not change.^{126, 137} Pravastatin has been accompanied by a 7% to 9% lowering of fibrinogen levels in 3 studies of 16 to 24 patients treated from 10 to 24 weeks.^138-140 Three studies reported no change in fibrinogen concentration with pravastatin.^{26, 141-142} However, KAPS reported a nonsignificant 7% elevation in fibrinogen in patients treated with either pravastatin and placebo for 3 years, but the increase in fibrinogen was 20% lower in the pravastatin group than in the placebo group.²⁶ Unlike the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial,¹⁴³ KAPS did not age adjust fibrinogen levels.²⁶ In addition, 2 pravastatin studies reported a reduction in whole blood viscosity at shear rates ranging from 75 to 375 seconds^-1, corrected blood viscosity at 112.5 seconds^-1 and 225 seconds^-1, and plasma viscosity.^{138, 140} Simvastatin does not change fibrinogen as shown in 4 studies of 12 to 111 subjects followed up for 10 weeks to 2 years.^{140, 142, 144-145} Additionally, blood, plasma and serum viscosity measurements were unchanged with simvastatin therapy.¹⁴⁴ Two comparative studies that randomized subjects to either pravastatin or simvastatin reported a favorable or neutral change in fibrinogen with pravastatin and a neutral change with simvastatin.^{140, 142} No published studies have evaluated the effect of fluvastatin on fibrinogen levels. Atorvastatin (80 mg daily) was accompanied by a 46% increase in fibrinogen levels in 22 heterozygous familial hypercholesterolemic subjects treated for 6 weeks.¹⁴⁶ The fibrinogen elevation was greater in subjects randomized to atorvastatin administered as a twice-daily dose compared to a single dose (P<.05). In 789 subjects, a lower dose of atorvastatin (10 mg daily) was accompanied by a smaller (4%) elevation in plasma fibrinogen levels.¹³⁵ Other investigators evaluated multiple dosages of atorvastatin (10-80 mg daily) on fibrinogen levels in 95 subjects and reported an increase in fibrinogen levels that ranged from 19% to 24%.¹⁴⁷

The variable effect of statins on fibrinogen may result from different actions on fibrinogen-regulating cytokines,⁷⁸ study populations with genetic variation at the fibrinogen gene locus,¹⁴⁸ or measurement variability.¹⁴⁹ Another factor to consider is age adjustment of fibrinogen levels in long-term studies.¹⁴³

Fibrinolytic Balance

Fibrinolytic mechanisms evaluated with statins include measurements of Lp(a) and PAI-1, the principal inhibitor of the fibrinolytic system. Impaired fibrinolysis as measured by an elevation in PAI-1 is predictive of ischemic heart disease in free-living subjects¹⁵⁰ and survivors of myocardial infarction.^150-152 Pravastatin reduces PAI-1 antigen levels by 26% to 56%,^{139, 141} and this appears to facilitate fibrinolysis. Lovastatin has been shown to both decrease PAI-1 by 22%¹³⁴ and elevate PAI-1 by 34% in 260 subjects.¹³⁵ Atorvastatin therapy increased PAI-1 by 36% after 12 months.¹³⁵ Simvastatin increased PAI-1 by 18% in 111 patients treated for 2 years.¹⁴⁵ Fluvastatin has a neutral effect on PAI-1 antigen.¹⁵³

Lipoprotein(a) interferes with fibrinolysis by competing with plasminogen binding to plasminogen receptors, fibrinogen, and fibrin.¹⁵⁴ The net effect is impaired plasminogen activation and plasmin generation at the thrombus surface.¹⁵⁵ The Lp(a) levels can increase by as much as 34% with statin therapy^156-160 and potentially impair clot lysis. Since the importance of Lp(a) on cardiovascular risk diminishes with LDL cholesterol–lowering therapy,¹⁵⁵ the importance of this modest evaluation in Lp(a) levels on overall cardiovascular risk is unclear. The opposing effects of statins on the different mediators of fibrinolysis may offset each other.

CONCLUSION

Jump to Section  • Top  • Introduction  • Ldl and cardiovascular events  • The vulnerable plaque and...  • Ldl and atherothrombogenesis  • Thrombotic factors  • Conclusion  • Author information  • References

Statins influence critical pathways that regulate plaque stability and thrombosis, and these properties extend beyond LDL lowering. The spectrum of direct antiatherogenic properties of statins includes maintenance of endothelial function, anti-inflammatory actions, and a permissive action on smooth muscle cell proliferation that allows for synthesis of extracellular matrix proteins involved in the reparative response. Following plaque disruption, statins influence thrombosis through variable inhibitory actions on platelet deposition and aggregation, coagulation factors, rheology, and fibrinolysis. The qualitative differences among statins may influence the effectiveness in the prevention of cardiovascular events and atherosclerosis disease progression.

Knowledge about the intricacies of atherosclerosis and thrombosis continues to expand rapidly, and these mechanisms should be used to support the evidence from randomized clinical trials. Since the nonlipid properties of statins differ despite comparable LDL cholesterol level lowering, the net clinical efficacy of these agents requires validation by randomized clinical trials.

AUTHOR INFORMATION

Jump to Section  • Top  • Introduction  • Ldl and cardiovascular events  • The vulnerable plaque and...  • Ldl and atherothrombogenesis  • Thrombotic factors  • Conclusion  • Author information  • References

This article is one of a series sponsored by the American Heart Association.

Dr Rosenson has received research support from Bristol Myers Squibb, Merck, and Parke Davis and serves on the Speaker's Bureau of Bristol Myers Squibb and Parke Davis. Dr Tangney has no financial support from any pharmaceutical company that manufactures or markets statins.

The authors acknowledge the contributions of Mary Lou Briglio for manuscript preparation.

Reprints: Robert S. Rosenson, MD, Preventive Cardiology Center, Rush-Presbyterian-St Luke's Medical Center, 1725 W Harrison St, Suite 1159, Chicago, IL 60612.

From the Preventive Cardiology Center, Departments of Medicine (Dr Rosenson) and Clinical Nutrition (Dr Tangney), Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill.

REFERENCES

Jump to Section  • Top  • Introduction  • Ldl and cardiovascular events  • The vulnerable plaque and...  • Ldl and atherothrombogenesis  • Thrombotic factors  • Conclusion  • Author information  • References

1. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol. 1995;6:386-388. FULL TEXT | WEB OF SCIENCE | PUBMED 2. Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH and the Harvard Atherosclerosis Reversibility Project Research Group. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypercholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol. 1995;76:78C-85C. FULL TEXT 3. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540. FREE FULL TEXT 4. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275. WEB OF SCIENCE | PUBMED 5. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-1445. FREE FULL TEXT 6. The Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Expert Panel Report of the National Cholesterol Education Program. Arch Intern Med. 1986;148:36-69. FULL TEXT 7. The Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023. FREE FULL TEXT 8. Study Group of the European Atherosclerosis Society. The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J. 1988;9:571-600. FREE FULL TEXT 9. The Canadian Consensus Conference on Cholesterol. Final report. Can Med Assoc J. 1988;26:369-388. 10. Pekkannen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relaxation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707. ABSTRACT 11. Pekkannen J, Tervahuata M, Nissinen A, Karvonen MJ. Does the predictive value of baseline coronary risk factors change over a 30-year follow-up? Cardiology. 1993;82:181-190. WEB OF SCIENCE | PUBMED 12. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA. 1995;274:801-806. FREE FULL TEXT 13. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835-2838. FREE FULL TEXT 14. Heinrich J, Ballaisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM Study in healthy men. Arterioscler Thromb. 1994;14:54-59. FREE FULL TEXT 15. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641. FREE FULL TEXT 16. Sweetnam PM, Thomas HF, Yarnell JWG, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity, and the 10-year incidence of ischaemic heart disease. Eur Heart J. 1996;17:1814-1820. FREE FULL TEXT 17. Tonkin A for the Long-term Intervention With Pravastatin in Ischemic Disease (LIPID) Paper presented at: 70th Scientific Sessions of the American Heart Association; November 12, 1997. Orlando, Fla. 18. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622. FREE FULL TEXT 19. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139. ABSTRACT 20. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/Liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037. FULL TEXT | WEB OF SCIENCE | PUBMED 21. Shepherd J, Cobb SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307. FREE FULL TEXT 22. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC II). Am J Cardiol. 1995;75:455-459. FULL TEXT | WEB OF SCIENCE | PUBMED 23. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687. FREE FULL TEXT 24. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009. FREE FULL TEXT 25. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968. FREE FULL TEXT 26. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-1764. FREE FULL TEXT 27. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study (MAAS). Lancet. 1994;344:633-638. FULL TEXT | WEB OF SCIENCE | PUBMED 28. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389. FULL TEXT | WEB OF SCIENCE | PUBMED 29. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976. FREE FULL TEXT 30. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162. FREE FULL TEXT 31. Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupal L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity. JAMA. 1992;267:816-822. FREE FULL TEXT 32. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than lower cholesterol. Lancet. 1996;348:1079-1082. FULL TEXT | WEB OF SCIENCE | PUBMED 33. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end points. Curr Opin Lipidol. 1996;7:389-397. WEB OF SCIENCE | PUBMED 34. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92:2419-2425. FREE FULL TEXT 35. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310:1137-1140. ABSTRACT 36. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br Heart J. 1985;53:363-373. FREE FULL TEXT 37. Libby P. Molecular basis of acute coronary syndromes. Circulation. 1995;91:2844-2850. FREE FULL TEXT 38. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671. FREE FULL TEXT 39. Davies MJ. Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture, 1995. Circulation. 1996;94:2013-2020. FREE FULL TEXT 40. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93:1354-1363. FREE FULL TEXT 41. Hackett D, Davies G, Maseri A. Preexisting coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J. 1988;9:1317-1323. FREE FULL TEXT 42. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496. FREE FULL TEXT 43. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989;135:169-175. ABSTRACT 44. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44. FREE FULL TEXT 45. Rekhter M, Zhang K, Narayanan A, Phan S, Schork M, Gordon D. Type I collagen gene expression in human atherosclerosis: localization to specific plaque regions. Am J Pathol. 1993;143:1634-1648. ABSTRACT 46. Warner SJC, Friedman GB, Libby P. Immune interferon inhibits proliferation and induces 2‘-5‘-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J Clin Invest. 1989;83:1174-1182. WEB OF SCIENCE | PUBMED 47. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 1991;11:1223-1230. FREE FULL TEXT 48. Shiomi M, Ito T, Tsukada T, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1938-1944. FREE FULL TEXT 49. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998;31:684-691. FREE FULL TEXT 50. Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases: a mechanistic clue to the "response to injury" hypothesis. Circulation. 1997;95:1760-1763. FREE FULL TEXT 51. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473-478. FREE FULL TEXT 52. Pedreno J, de Castellarnau C, Cullare C, et al. LDL binding sites on platelets differ from the "classical" receptor of nucleated cells. Arterioscler Thromb. 1992;12:1353-1362. FREE FULL TEXT 53. Chen LY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation. 1996;93:1740-1746. FREE FULL TEXT 54. Hassall DG, Owens JS, Bruckdorfer KR. The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin. Biochem J. 1983;216:43-49. WEB OF SCIENCE | PUBMED 55. Dentan C, Lesnik P, Chapman MJ, Ninio E. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation. Arterioscler Thromb. 1994;14:353-360. FREE FULL TEXT 56. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol. 1992;29:159-169. WEB OF SCIENCE | PUBMED 57. Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VII activity in plasma requires factor X and an additional plasma component. Blood. 1985;66:204-212. FREE FULL TEXT 58. Woodward M, Lowe GDO, Rumley A, et al. Epidemiology of coagulation factors, inhibitors and activation markers, the Third Glasgow MONICA Survey II: relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1997;97:785-797. FULL TEXT | WEB OF SCIENCE | PUBMED 59. Rosenson RS, Lowe GDO. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis. 1998;140:271-280. FULL TEXT | WEB OF SCIENCE | PUBMED 60. Balleisen L, Assmann G, Bailey J, Epping P-H, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population, II: baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost. 1985;54:721-723. WEB OF SCIENCE | PUBMED 61. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 1993;341:1496-1500. FULL TEXT | WEB OF SCIENCE | PUBMED 62. Anderson TJ, Gerhard MD, Meredith IT, et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75:71B-74B. FULL TEXT | WEB OF SCIENCE | PUBMED 63. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524. FREE FULL TEXT 64. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487. FREE FULL TEXT 65. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493. FREE FULL TEXT 66. Winniford M, Hodgson J, Yeung A, et al. CARAT Study: the effect of cholesterol lowering on coronary blood flow. Study presented at: 66th Congress of the European Atherosclerosis Society; July 1996; Florence, Italy. 67. Stroes ESG, Koomans HA, deBruin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346:467-471. FULL TEXT | WEB OF SCIENCE | PUBMED 68. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol. 1996;77:37-40. FULL TEXT | WEB OF SCIENCE | PUBMED 69. Hayoz D, Weber R, Rutschmann B, et al. Postischemic blood flow response in hypercholesterolemic patients. Hypertension. 1995;26:497-502. FREE FULL TEXT 70. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126-1131. FREE FULL TEXT 71. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AVG. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 1996;94:1503-1505. FREE FULL TEXT 72. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324-328. FREE FULL TEXT 73. Eichstadt HW, Eskotter H, Hoffmann I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol. 1995;76:122A-125A. 74. Aengevaeren WRM, Uijen GJH, Jukema JW, Bruschke AVG, Werf T. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study. Circulation. 1997;96:429-435. FREE FULL TEXT 75. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol. 1995;75:582-586. FULL TEXT | WEB OF SCIENCE | PUBMED 76. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 1997;349:1391-1392. FULL TEXT | WEB OF SCIENCE | PUBMED 77. Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997;95:2387-2394. FREE FULL TEXT 78. Green F, Humphries S. Control of plasma fibrinogen levels. Baillieres Clin Haematol. 1989;2:945-959. FULL TEXT | PUBMED 79. Padgett RC, Heistad DD, Mugge A, Armstrong ML, Piegors DJ, Lopez JAG. Vascular responses to activated leukocytes after regression of atherosclerosis. Circ Res. 1992;70:423-429. FREE FULL TEXT 80. Weber C, Erl W, Weber KSC, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212-1217. ABSTRACT 81. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol. 1997;17:1521-1526. FREE FULL TEXT 82. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627. FREE FULL TEXT 83. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2:941-944. FULL TEXT | WEB OF SCIENCE | PUBMED 84. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathological correlation. Circulation. 1993;87:1179-1187. FREE FULL TEXT 85. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86:2839-2843. FREE FULL TEXT 86. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569. ABSTRACT 87. Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis. 1993;104:19-26. FULL TEXT | WEB OF SCIENCE | PUBMED 88. Kempen HJM, Vermeer M, deWit E, Havekes LM. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages. Arterioscler Thromb. 1991;11:146-153. FREE FULL TEXT 89. Armstrong ML, Warner E, Connor W. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970;27:59-67. FREE FULL TEXT 90. Clarkson TB, Bond MG, Bullock BC, Marzetta CA. A study of atherosclerosis regression in Macaca mulatta. Exp Mol Pathol. 1981;34:345-368. FULL TEXT | WEB OF SCIENCE | PUBMED 91. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physiocochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984;73:1590-1605. WEB OF SCIENCE | PUBMED 92. Small DM. Progression and regression of atherosclerotic lesions: insights from lipid physical biochemistry. Arteriosclerosis. 1988;8:103-129. FREE FULL TEXT 93. deGraaf J, Hak-Lemmers HLM, Hectors MPC, Demaker PCM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 1991;11:298-306. FREE FULL TEXT 94. Navab M, Berliner JA, Watson AD, et al. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996;16:831-842. FREE FULL TEXT 95. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881. FREE FULL TEXT 96. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888. FREE FULL TEXT 97. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 1996;94:2146-2153. FREE FULL TEXT 98. Salonen R, Nyyssonen K, Porkkala-Sarataho E, et al. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 1995;76:34C-39C. 99. Hoffman R, Brook GJ, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis. 1992;93:105-113. FULL TEXT | WEB OF SCIENCE | PUBMED 100. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism. 1992;41:229-235. FULL TEXT | WEB OF SCIENCE | PUBMED 101. Brosche T, Kral C, Summa JD, Platt D. Effective lovastatin therapy in elderly hypercholesterolemic patients—an antioxidative impact? Arch Gerontol Geriatr. 1996;22:207-221. WEB OF SCIENCE | PUBMED 102. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33:226-229. ABSTRACT 103. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baurn H, Quinn PF. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol. 1993;46:1055-1057. FREE FULL TEXT 104. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1993;1165: 335-338. 105. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996;77:851-854. FULL TEXT | WEB OF SCIENCE | PUBMED 106. Willis RA, Folkers K, Tucker JL, Ye CQ, Xia LJ, Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci U S A. 1990;87:8928-8930. FREE FULL TEXT 107. Marinari UM, Pronzato MA, Dapino D, et al. Effects of simvastatin on liver and plasma levels of cholesterol, dolichol and ubiquinol in hypercholesterolemic rats. Ital J Biochem. 1995;44:1-9. WEB OF SCIENCE | PUBMED 108. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet. 1996;347:305-307. FULL TEXT | WEB OF SCIENCE | PUBMED 109. Cheng GC, Libby P, Grodzinsky AJ, Lee RT. Induction of DNA synthesis by a single transient mechanical stimulus of human vascular smooth muscle cells: role of fibroblast growth factor-2. Circulation. 1996;93:99-105. FREE FULL TEXT 110. Soma MR, Donetti E, Parolini C, et al. HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb. 1993;13:571-578. FREE FULL TEXT 111. Corsini A, Raiteri M, Soma M, Fumagalli R, Paoletti R. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res. 1991;23:173-180. FULL TEXT | WEB OF SCIENCE | PUBMED 112. Negre-Aminoux P, van Vliet AK, van Erck M, et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochim Biophys Acta. 1997;1345:259-268. PUBMED 113. Igarashi M, Takeda Y, Mori S, et al. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol. 1997;120:1172-1178. FULL TEXT | WEB OF SCIENCE | PUBMED 114. Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet. 1996;348:1584. WEB OF SCIENCE | PUBMED 115. Nemerson Y. Tissue factor and haemostasis. Blood. 1988;71:1-8. FREE FULL TEXT 116. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. Arterioscler Thromb Vasc Biol. 1997;17:265-272. FREE FULL TEXT 117. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb. 1993;13:1066-1075. FREE FULL TEXT 118. Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb. 1991;11:138-145. FREE FULL TEXT 119. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 1994;14:223-229. FREE FULL TEXT 120. Zitoun D, Bara L, Basdevant A, Samama MM. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler Thromb Vasc Biol. 1996;16:77-81. FREE FULL TEXT 121. Carvalho AC, Colman RW, Less RS. Platelet function in hyperlipoproteinemia. N Engl J Med. 1974;290:434-438. WEB OF SCIENCE | PUBMED 122. Nofer JR, Tepel M, Kehrel B, et al. Low-density lipoproteins inhibit the Na⁺/H⁺ antiport in human platelets: a novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation. 1997;95:1370-1377. FREE FULL TEXT 123. van Willigan G, Gorter G, Akkerman JWN. LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb. 1994;14:41-46. FREE FULL TEXT 124. Davi G, Averna M, Novo S, et al. Effects of synvinolin on platelet aggregation and thromboxane B₂ synthesis in type IIa hypercholesterolemic patients. Atherosclerosis. 1989;79:79-83. FULL TEXT | WEB OF SCIENCE | PUBMED 125. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247-251. FREE FULL TEXT 126. Beigel Y, Fuchs J, Snir M, Green P, Lurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol. 1991;31:512-517. ABSTRACT 127. Mayer J, Eller T, Brauer P, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992;64:196-201. FULL TEXT | WEB OF SCIENCE | PUBMED 128. Aoki I, Aoki A, Kawano K, et al. Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol. 1997;30:91-96. ABSTRACT 129. Le Quan Sang KH, Levenson J, Megnien JL, Simon A, Devynck MA. Platelet cytosolic Ca²⁺ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol. 1995;15:759-764. FREE FULL TEXT 130. Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92:3172-3177. FREE FULL TEXT 131. Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients. J Am Coll Cardiol. 1996;27:413A. 132. Rosenson RS. Viscosity and ischemic heart disease. J Vasc Med Biol. 1993;4:206-212. 133. Rosenson RS, Tangney CC. Beneficial effects of statins. Lancet. 1996;348:1583. WEB OF SCIENCE | PUBMED 134. Isaacsohn J, Setaro JF, Nicholas C, et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol. 1994;74:735-737. FULL TEXT | WEB OF SCIENCE | PUBMED 135. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481. FULL TEXT | WEB OF SCIENCE | PUBMED 136. Koenig W, Hehr R, Ditschuneit HH, et al. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)? J Clin Pharmacol. 1992;32:539-545. FREE FULL TEXT 137. Koppensteiner R, Minar E, Ehringer H. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis. 1990;83:53-58. FULL TEXT | WEB OF SCIENCE | PUBMED 138. Jay RH, Ramply MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolemia: effects of treatment. Am J Cardiol. 1993;72:1031-1037. FULL TEXT | WEB OF SCIENCE | PUBMED 139. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani G. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr Ther Res Clin Exp. 1994;55:1335-1344. FULL TEXT | WEB OF SCIENCE 140. Tsuda Y, Satoh K, Kitadai M, et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 1996;122:225-233. FULL TEXT | WEB OF SCIENCE | PUBMED 141. Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther. 1992;14:829-834. WEB OF SCIENCE | PUBMED 142. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost. 1993;70:241-243. WEB OF SCIENCE | PUBMED 143. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208. FREE FULL TEXT 144. Bo M, Bonino F, Neirotti M, et al. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology. 1991;42:106-113. FREE FULL TEXT 145. Mitropoulos KA, Armitage JM, Collins R, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. Eur Heart J. 1997;18:235-241. FREE FULL TEXT 146. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17:1527-1531. FREE FULL TEXT 147. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet. 1998;351:569-570. FULL TEXT | WEB OF SCIENCE | PUBMED 148. Behague I, Poirier O, Nicaud V, et al. Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM Study. Circulation. 1996;93:440-449. FREE FULL TEXT 149. Rosenson RS, Tangney CC, Hafner JM. Intraindividual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb. 1994;14:1928-1932. FREE FULL TEXT 150. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079. FULL TEXT | WEB OF SCIENCE | PUBMED 151. Hamsten A, Wiman B, De Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563. ABSTRACT 152. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG for the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation. 1996;94:2057-2063. FREE FULL TEXT 153. Bevilacqua M, Bettica P, Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol. 1997;79:84-87. FULL TEXT | WEB OF SCIENCE | PUBMED 154. Stein JH, Rosenson RS. Lipoprotein(a) and coronary heart disease. Arch Intern Med. 1997;157:1170-1176. FREE FULL TEXT 155. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989;86:3847-3851. FREE FULL TEXT 156. Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis. 1988;73: 135-141. 157. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80:1313-1319. FREE FULL TEXT 158. Slunga L, Johnson O, Dahlen GH. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolemia with simvastatin. Eur J Clin Pharmacol. 1992;43:369-373. FULL TEXT | WEB OF SCIENCE | PUBMED 159. Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol. 1995;18:261-267. WEB OF SCIENCE | PUBMED 160. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein(a). J Clin Pharmacol. 1993;33:574-580. ABSTRACT

Clinical Cardiology section editors: Bruce Brundage, MD, University of California, Los Angeles School of Medicine; Margaret A. Winker, MD, Senior Editor, JAMA.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial
I. U. Haq, E. J. Wallis, W. W. Yeo, P. R. Jackson, L. E. Ramsay, Louis H. Krut, David E. Kandzari, Pascal J. Goldschmidt-Clermont, James M. Mason, Nick Freemantle, Todd D. McDiarmid, William A. Hensel, John A. Papadakis, Dimitri P. Mikhailidis, Judith Walsh, David Siegel, Arthur L. M. Swislocki, John R. Downs, Antonio M. Gotto, Jr, Michael Clearfield, Stephen Weis, Robert S. Rosenson, and Christine C. Tangney
JAMA. 1999;281(5):414-419.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
John R. Downs, Michael Clearfield, Stephen Weis, Edwin Whitney, Deborah R. Shapiro, Polly A. Beere, Alexandra Langendorfer, Evan A. Stein, William Kruyer, Antonio M. Gotto, Jr, and for the AFCAPS/TexCAPS Research Group
JAMA. 1998;279(20):1615-1622.
ABSTRACT | FULL TEXT  

Lipid-Lowering Therapy in Low-Risk Patients
Thomas A. Pearson
JAMA. 1998;279(20):1659-1661.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Novel Approaches for Preventing or Limiting Events (Naples) II Trial: Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction
Briguori et al.
J Am Coll Cardiol 2009;54:2157-2163.
ABSTRACT | FULL TEXT  

Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA)
Authors/Task Force Members et al.
Eur Heart J 2009;30:2769-2812.
FULL TEXT  

American Diabetes Association Indications for Statins in Diabetes: Is there evidence?
Eldor and Raz
Diabetes Care 2009;32:S384-S391.
FULL TEXT  

Statins in Acute Coronary Syndromes: Do the Guideline Recommendations Match the Evidence?
Morrissey et al.
J Am Coll Cardiol 2009;54:1425-1433.
ABSTRACT | FULL TEXT  

Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury
Redecha et al.
Blood 2009;113:4101-4109.
ABSTRACT | FULL TEXT  

PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study
Schlitt et al.
J. Lipid Res. 2009;50:723-729.
ABSTRACT | FULL TEXT  

Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study
Almroth et al.
Eur Heart J 2009;30:827-833.
ABSTRACT | FULL TEXT  

CD4+CD28null T cells in coronary artery disease: when helpers become killers
Dumitriu et al.
Cardiovasc Res 2009;81:11-19.
ABSTRACT | FULL TEXT  

The impact of statin use on atrial fibrillation
Sanchez-Quinones et al.
QJM 2008;101:845-861.
ABSTRACT | FULL TEXT  

Association of Soluble Cell Adhesion Molecules with Ankle-Brachial Index in a Biethnic Cohort of Predominantly Hypertensive Individuals
Khaleghi et al.
Clin. Chem. 2008;54:1788-1795.
ABSTRACT | FULL TEXT  

HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
Mallewa et al.
J Antimicrob Chemother 2008;62:648-660.
ABSTRACT | FULL TEXT  

Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports
Fernandez et al.
Chest 2008;134:824-830.
ABSTRACT | FULL TEXT  

Unraveling Pleiotropic Effects Of Statins: Bit By Bit, a Slow Case With Perspective
Arslan et al.
Circ. Res. 2008;103:334-336.
FULL TEXT  

Effect of Pretreatment With Statins on Ischemic Stroke Outcomes
Reeves et al.
Stroke 2008;39:1779-1785.
ABSTRACT | FULL TEXT  

Preprocedural Statin Therapy in Percutaneous Coronary Intervention
Cahoon and Crouch
The Annals of Pharmacotherapy 2007;41:1687-1693.
ABSTRACT | FULL TEXT  

Do statins have an antiarrhythmic activity?
Kostapanos et al.
Cardiovasc Res 2007;75:10-20.
ABSTRACT | FULL TEXT  

Modulation of COX-2 expression by statins in human monocytic cells
Habib et al.
FASEB J. 2007;21:1665-1674.
ABSTRACT | FULL TEXT  

Markers of inflammation are inversely associated with VO2 max in asymptomatic men
Kullo et al.
J. Appl. Physiol. 2007;102:1374-1379.
ABSTRACT | FULL TEXT  

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy
Yu et al.
Diabetes and Vascular Disease Research 2006;3:189-196.
ABSTRACT  

Direct Demonstration of an Antiinflammatory Effect of Simvastatin in Subjects with the Metabolic Syndrome
Devaraj et al.
J. Clin. Endocrinol. Metab. 2006;91:4489-4496.
ABSTRACT | FULL TEXT  

Sex Difference in the Antiplatelet Effect of Aspirin in Patients with Stroke
Cavallari et al.
The Annals of Pharmacotherapy 2006;40:812-817.
ABSTRACT | FULL TEXT  

Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk
Kumar et al.
Neurology 2006;66:1153-1158.
ABSTRACT | FULL TEXT  

Pitavastatin Effect on ATP Binding Cassette A1-Mediated Lipid Efflux from Macrophages: Evidence for Liver X Receptor (LXR)-Dependent and LXR-Independent Mechanisms of Activation by cAMP
Zanotti et al.
J. Pharmacol. Exp. Ther. 2006;317:395-401.
ABSTRACT | FULL TEXT  

Pravastatin and Clopidogrel Combined Inhibit Intimal Hyperplasia in a Rat Carotid Endarterectomy Model
Bledsoe et al.
VASC ENDOVASCULAR SURG 2006;40:49-57.
ABSTRACT  

Statins and cognitive function in the elderly: The Cardiovascular Health Study
Bernick et al.
Neurology 2005;65:1388-1394.
ABSTRACT | FULL TEXT  

Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis
Herman and Moncada
Eur Heart J 2005;26:1945-1955.
ABSTRACT | FULL TEXT  

Intensive lipid lowering with atorvastatin in coronary disease.
Auer et al.
NEJM 2005;353:93-96.
FULL TEXT  

Effects of Cholesterol-Lowering Statins on the Aqueous Humor Outflow Pathway
Song et al.
IOVS 2005;46:2424-2432.
ABSTRACT | FULL TEXT  

Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial
Geluk et al.
Eur Heart J 2005;26:1314-1320.
ABSTRACT | FULL TEXT  

Statin Use and the Risk of Incident Dementia: The Cardiovascular Health Study
Rea et al.
Arch Neurol 2005;62:1047-1051.
ABSTRACT | FULL TEXT  

Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction?
Lorenz et al.
Eur Heart J 2005;26:1078-1085.
ABSTRACT | FULL TEXT  

Effect of Different Antilipidemic Agents and Diets on Mortality: A Systematic Review
Studer et al.
Arch Intern Med 2005;165:725-730.
ABSTRACT | FULL TEXT  

Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: The Statins for Risk Reduction in Surgery (StaRRS) study
O'Neil-Callahan et al.
J Am Coll Cardiol 2005;45:336-342.
ABSTRACT | FULL TEXT  

Statins and Blood Coagulation
Undas et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:287-294.
ABSTRACT | FULL TEXT  

Intensive Lipid-Lowering Therapy in Patients with Coronary Heart Disease
Lauderdale and Sheehan
The Annals of Pharmacotherapy 2005;39:329-334.
ABSTRACT | FULL TEXT  

The Potential Role of HMG-CoA Reductase Inhibitors in Pediatric Nephrotic Syndrome
Prescott et al.
The Annals of Pharmacotherapy 2004;38:2105-2114.
ABSTRACT | FULL TEXT  

Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis
Amarenco et al.
Stroke 2004;35:2902-2909.
ABSTRACT | FULL TEXT  

Early Withdrawal of Statin Therapy in Patients With Non-ST-Segment Elevation Myocardial Infarction: National Registry of Myocardial Infarction
Spencer et al.
Arch Intern Med 2004;164:2162-2168.
ABSTRACT | FULL TEXT  

Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep
Zhou et al.
Blood 2004;104:2353-2358.
ABSTRACT | FULL TEXT  

Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction
Briguori et al.
Eur Heart J 2004;25:1822-1828.
ABSTRACT | FULL TEXT  

Role of Endothelial Dysfunction in Atherosclerosis
Davignon and Ganz
Circulation 2004;109:III-27-III-32.
ABSTRACT | FULL TEXT  

Statins for Stroke Prevention: Disappointment and Hope
Amarenco and Tonkin
Circulation 2004;109:III-44-III-49.
ABSTRACT | FULL TEXT  

Association of Statin Therapy with Outcomes of Acute Coronary Syndromes: The GRACE Study
Spencer et al.
ANN INTERN MED 2004;140:857-866.
ABSTRACT | FULL TEXT  

Coronary Event Secondary Prevention with Statins Irrespective of LDL-Cholesterol
Kerst and Mauro
The Annals of Pharmacotherapy 2004;38:1060-1064.
ABSTRACT | FULL TEXT  

Cholesterol Is Associated With Stroke, but Is Not a Risk Factor
Thrift
Stroke 2004;35:1524-1525.
FULL TEXT  

Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses?
Watts
Eur Heart J 2004;25:716-719.
FULL TEXT  

Protective Role of Imatinib in Atherosclerosis
Kadowaki and Kubota
Arterioscler. Thromb. Vasc. Bio. 2004;24:801-803.
FULL TEXT  

Favorable Outcome of Ischemic Stroke in Patients Pretreated with Statins
Marti-Fabregas et al.
Stroke 2004;35:1117-1121.
ABSTRACT | FULL TEXT  

Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians
Snow et al.
ANN INTERN MED 2004;140:644-649.
ABSTRACT | FULL TEXT  

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure
Horwich et al.
J Am Coll Cardiol 2004;43:642-648.
ABSTRACT | FULL TEXT  

Pitavastatin Downregulates Expression of the Macrophage Type B Scavenger Receptor, CD36
Han et al.
Circulation 2004;109:790-796.
ABSTRACT | FULL TEXT  

Commentary: Development of Mendelian randomization: from hypothesis test to 'Mendelian deconfounding'
Tobin et al.
Int J Epidemiol 2004;33:26-29.
FULL TEXT  

Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy
Li et al.
Am. J. Physiol. Renal Physiol. 2004;286:F46-F57.
ABSTRACT | FULL TEXT  

Cholesterol and the Risk of Ischemic Stroke
Bowman et al.
Stroke 2003;34:2930-2934.
ABSTRACT | FULL TEXT  

Primary Prevention of Coronary Heart Disease in the Elderly
Dornbrook-Lavender et al.
The Annals of Pharmacotherapy 2003;37:1654-1663.
ABSTRACT | FULL TEXT  

Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models
Susic et al.
J Am Coll Cardiol 2003;42:1091-1097.
ABSTRACT | FULL TEXT  

Genetic and Acquired Determinants of Individual Variability of Response to Antiplatelet Drugs
Schafer
Circulation 2003;108:910-911.
FULL TEXT  

Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: Coronary artery disease regression single photon emission computed tomography monitoring trial
Schwartz et al.
J Am Coll Cardiol 2003;42:600-610.
ABSTRACT | FULL TEXT  

Hemostatic Effects of Atorvastatin Versus Simvastatin
Kadikoylu et al.
The Annals of Pharmacotherapy 2003;37:478-484.
ABSTRACT | FULL TEXT  

Differential Effects of Lipid-Lowering Therapies on Stroke Prevention: A Meta-analysis of Randomized Trials
Corvol et al.
Arch Intern Med 2003;163:669-676.
ABSTRACT | FULL TEXT  

Statin effects beyond lipid lowering--are they clinically relevant?
Bonetti et al.
Eur Heart J 2003;24:225-248.
FULL TEXT  

Estrogen and Stroke: A Balanced Analysis
Hurn and Brass
Stroke 2003;34:338-341.
FULL TEXT  

Fluvastatin Prevents Renal Dysfunction and Vascular NO Deficit in Apolipoprotein E-Deficient Mice
Gervais et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:183-189.
ABSTRACT | FULL TEXT  

Statin Therapy Interacts With Cytomegalovirus Seropositivity and High C-Reactive Protein in Reducing Mortality Among Patients With Angiographically Significant Coronary Disease
Horne et al.
Circulation 2003;107:258-263.
ABSTRACT | FULL TEXT  

Statins and stroke: evidence for cholesterol-independent effects
Di Napoli et al.
Eur Heart J 2002;23:1908-1921.
 

Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial
Liem et al.
Eur Heart J 2002;23:1931-1937.
ABSTRACT  

Atherogenesis--recent insights into basic mechanisms and their clinical impact
Schachinger and Zeiher
Nephrol Dial Transplant 2002;17:2055-2064.
FULL TEXT  

Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community
Bellamy et al.
J Am Coll Cardiol 2002;40:1723-1730.
ABSTRACT | FULL TEXT  

Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival
Mehra et al.
J Am Coll Cardiol 2002;40:1609-1614.
ABSTRACT | FULL TEXT  

Unraveling Pleiotropic Effects of Statins on Plaque Rupture
Palinski and Napoli
Arterioscler. Thromb. Vasc. Bio. 2002;22:1745-1750.
FULL TEXT  

Low-Density Lipoprotein Lowering and Atherosclerosis Progression: Does More Mean Less?
Shah
Circulation 2002;106:2039-2040.
FULL TEXT  

ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness
Taylor et al.
Circulation 2002;106:2055-2060.
ABSTRACT | FULL TEXT  

Statin Lipid-Lowering Therapy for Acute Myocardial Infarction and Unstable Angina: Efficacy and Mechanism of Benefit
Wright et al.
Mayo Clin Proc. 2002;77:1085-1092.
ABSTRACT  

Treating to goal: new strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis
Fonarow
Vasc Med 2002;7:187-194.
ABSTRACT  

Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With Dyslipidemia
Chan et al.
Diabetes 2002;51:2377-2386.
ABSTRACT | FULL TEXT  

Cholesterol Predicts Stroke Mortality in the Women's Pooling Project
Horenstein et al.
Stroke 2002;33:1863-1868.
ABSTRACT | FULL TEXT  

Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS)
Herrington et al.
Circulation 2002;105:2962-2967.
ABSTRACT | FULL TEXT  

Therapy With Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors (Statins) and Associated Risk of Incident Cardiovascular Events in Older Adults: Evidence From the Cardiovascular Health Study
Lemaitre et al.
Arch Intern Med 2002;162:1395-1400.
ABSTRACT | FULL TEXT  

Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease
Franz Alber et al.
J Am Coll Cardiol 2002;39:1951-1955.
ABSTRACT | FULL TEXT  

Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes
Newby et al.
JAMA 2002;287:3087-3095.
ABSTRACT | FULL TEXT  

Reducing cholesterol and atherosclerosis
Hornung
QJM 2002;95:339-341.
FULL TEXT  

Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity
Chan et al.
Clin. Chem. 2002;48:877-883.
ABSTRACT | FULL TEXT  

Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis
Palinski and Tsimikas
J. Am. Soc. Nephrol. 2002;13:1673-1681.
ABSTRACT | FULL TEXT  

Reversal of Thrombin-Induced Deactivation of CD39/ATPDase in Endothelial Cells by HMG-CoA Reductase Inhibition: Effects on Rho-GTPase and Adenosine Nucleotide Metabolism
Kaneider et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:894-900.
ABSTRACT | FULL TEXT  

Rho-GTPase-Dependent Platelet-Neutrophil Interaction Affected by HMG-CoA Reductase Inhibition With Altered Adenosine Nucleotide Release and Function
Kaneider et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:1029-1035.
ABSTRACT | FULL TEXT  

Statins and chronic heart failure: do we need a large-scale outcome trial?
Krum and McMurray
J Am Coll Cardiol 2002;39:1567-1573.
ABSTRACT | FULL TEXT  

Short-term effects of atorvastatin on C-reactive protein
Riesen et al.
Eur Heart J 2002;23:794-799.
ABSTRACT | FULL TEXT  

Pleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane et al.
J. Clin. Endocrinol. Metab. 2002;87:1451-1458.
ABSTRACT | FULL TEXT  

Fluvastatin Reduces Tissue Factor Expression and Macrophage Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits in the Absence of Lipid Lowering
Baetta et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:692-698.
ABSTRACT | FULL TEXT  

Lipid lowering and the assessment of endothelial function
Lee et al.
Cardiovasc Res 2002;54:191-192.
FULL TEXT  

Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
Yaffe et al.
Arch Neurol 2002;59:378-384.
ABSTRACT | FULL TEXT  

Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review
Gorelick
Stroke 2002;33:862-875.
ABSTRACT | FULL TEXT  

Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project
Simes et al.
Eur Heart J 2002;23:207-215.
ABSTRACT